UBC - CPD 17th Annual Pacific Psychopharmacology Conference
Registration now open
Sept. 29 (Fri) | 8:10 a.m.–3:45 p.m. | Pinnacle Harbourfront Hotel, Vancouver, BC | Hybrid
Audience: family physicians, psychiatrists, pharmacists, mental health specialists, psychologists, nurse practitioners, nurses, social workers, residents and students.
Overview: We are excited to welcome a world-class lineup of experts for this year’s program. International and local speakers will share their expertise on a range of psychiatric disorders and psychopharmacology topics.
Up to 5.5 Mainpro+/MOC Section 1 credits

LEARN MORE & REGISTER

Can’t join us live?

Registration includes access to all the recorded plenaries and four workshops to watch on demand for up to 3 months after the event.


Invited Speakers: 

Treatments for Psychosis
Philip McGuire
MB, ChB, MD, PhD, FRCPsych, FMedSci
Professor of Psychiatry, Department of Psychiatry, University of Oxford; Co-Lead for Precision Psychiatry, NIHR Oxford Health Biomedical Research Centre(lecture delivered virtually)

Diagnosing & Treating Bipolar Spectrum Disorders
Andrew Nierenberg
MD, Endowed Chair in Psychiatry
Professor of Psychiatry, Harvard Medical School; Director, Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital

Recent Advances in the Psychopharmacology of ADHD
Margaret D. Weiss
MD, PhD, FRCPC
Associate Professor of Psychiatry and Director of Clinical Research at Cambridge Health Alliance

Practical Prescribing for Insomnia in Older Adults
Elliott Lee
MD, FRCPC, D.ABSM, F.AASM, APA
Assistant Professor and Sleep Specialist, Royal Ottawa Mental Health Center, University of Ottawa


Pre-conference workshop:

Exploring the Psychedelic Frontier: Ketamine’s Role in Transforming Depression Treatment
Sept. 28 (Thu) | 1–4 p.m. | Pinnacle Harbourfront Hotel, Vancouver, BC | Hybrid
Join us as we delve into the promising role of ketamine in revolutionizing the treatment of depression. Through a captivating exploration of the psychedelic frontier, we will examine the profound effects of ketamine on alleviating depressive symptoms and its potential to reshape the landscape of mental health care.
Up to 3.0 Mainpro+/MOC Section 1 credits